Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-01
2008-07-01
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
10883646
ABSTRACT:
Compounds of Formula Iand all pharmaceutically acceptable forms thereof, are described herein.The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein.Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein.Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases.Other embodiments include methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease responsive to inhibition of kinase activity.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent.A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample.
REFERENCES:
patent: 5593997 (1997-01-01), Dow et al.
patent: 5658857 (1997-08-01), Andree et al.
patent: 5783576 (1998-07-01), Roos et al.
patent: 6919341 (2005-07-01), Paruch et al.
patent: 2003/0212073 (2003-11-01), Currie et al.
patent: 2004/0063715 (2004-04-01), Paruch et al.
patent: 2004/0067951 (2004-04-01), DeSimone et al.
patent: 2004/0072835 (2004-04-01), Paruch et al.
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 0 43 37 609 (1995-05-01), None
patent: 0 480 713 (1992-04-01), None
patent: WO 88/04298 (1988-06-01), None
patent: WO 95/12594 (1995-05-01), None
patent: WO 96/04298 (1996-02-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 99/28322 (1999-06-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 02/10170 (2002-02-01), None
patent: WO 02/30428 (2002-04-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 03/089434 (2003-10-01), None
patent: WO 2004/022562 (2004-03-01), None
patent: WO 2004/026310 (2004-04-01), None
patent: WO 2004/026877 (2004-04-01), None
patent: WO 2004/072080 (2004-08-01), None
patent: WO 2004/072081 (2004-08-01), None
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Vassilev and Uckun “Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK)” Current Pharmaceutical Design, vol. 10, pp. 1757-1766 (2004).
Ding et al. (2002) “A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries,” J. Am. Chem. Soc., 124(8): 1594-1596.
Hanks (Apr. 1, 1994) “Hanks Classification: Protein Kinase Classification, provided by Steven K. Hanks,” pp. 1-4, from http://pkr.sdsc.edu/html/pk—classification/pk—catalytic/pk—hanks—class.html.
Jeffrey et al. (1998) “Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension,” J. Cardiovascular Pharmacology, 32:213-219.
Lumma Jr. et al. (1983) “Piperazinylimidazo[1,2-a]pyrazines with Selective Affinity for in Vitro alpha-Adrenergic Receptor Subtypes,” J. Med. Chem., 26:357-363.
“Protein Kinases in Disease,” references produced from a Sep. 24, 1997, search of the On-line Meddelian Inheritance in Man (OMIM) database, pp. 1-11, from http://bioinformatics.weizmann.ac.il/Kinases/pkr/pk—medicine.html.
Stenberg et al. (2000) “KinMutBase, a database of human disease-causing protein kinase mutations,” Nucleic Acids Research, 28(1):369-371.
Vitse et al. (1999) “New Imidazo[1,2-a]pyrazine Derivatives with Brochodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities,” Bioorganic & Medicinal Chemistry, 7: 1059-1065.
Restriction Requirement dated Oct. 20, 2004, for U.S. Appl. No. 10/419,682, filed Apr. 21, 2003.
International Search Report dated Oct. 22, 2003, for Application No. PCT/US03/1222, International filing date Apr. 21, 2003.
Written Opinion dated Dec. 5, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Second Written Opinion dated Apr. 13, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Preliminary Examination Report dated Aug. 3, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Search Report dated Feb. 9, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
Written Opinion dated Jul. 6, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Preliminary Examination Report dated Oct. 27, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003922, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003923, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Dec. 8, 2004, for Application No. PCT/US2004/021150, International filing date Jun. 30, 2004.
Tsukada, S., et al.,Deficient expression of a B cell cytoplasmic kinase in human X-linked agammaglobulinemia. Cell, 1993. 72: p. 279-290.
Vetrie, D., et al.,The gene involved in X-linked agammaglobulinemia is a member of the src family of protein kinases. Nature, 1993. 361: p. 226-233.
Steinberg, B.J., et al.,Ability of the xid gene to prevent autoimmunity in(NZB X NZW)Fl mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest, 1982. 70(3): p. 587-597.
Smith, H.R., T.M. Chused, and A.D. Steinberg,The Effect of the X-linked Immune Deficiency Gene(xid)upon the Y Chromosome-Related Disease of BXSB Mice. The Journal of Immunology, 1983. 131: p. 1257-1262.
Steinberg, E.B., et al.,Studies of Congenic MRL-lpr/lpr.xid Mice. The Journal of Immunology, 1983. 131(2789-2795).
Fieser, T.M., et al.,Abrogation of Murine Lupus by the xid Gene is Associated with Reduced Responsiveness of B Cells to T-Cell-Helper Signals. Cellular Immunology, 1984. 87: p. 708-713.
Steinberg, A.D., et al.,Systemic Lupus Erythematosus: Insights from Animal Models. Annals of Internal Medicine, 1984. 100: p. 714-727.
Reeves, J.P. and A.D. Steinberg,Effect of the xid Gene on Graft-versus-Host-Induced Autoantibody Production in Nonautoimmune Mice. Clinical Immunology and Imunopathology, 1985. 36: p. 320-329.
Jansson, L. and R. Holmdahl,Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol, 1993. 94: p. 459-465.
Zhao, Y.X., et al.,Mice with the xid B cell defect are less susceptible to developing Staphylococcus a
Currie Kevin S.
DeSimone Robert W.
Mitchell Scott A.
Pippin Douglas A.
CGI Pharmaceuticals, Inc.
Millen White Zelano & Branigan P.C.
Tucker Zachary C
LandOfFree
Certain heterocyclic substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain heterocyclic substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain heterocyclic substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3923412